Skip to main content
  • Less DAPT Can Help Avoid Bleeding in High-Risk Patients Post-PCI – CRT Session

    The TWILIGHT studies’ findings support the use of ticagrelor in selected high-risk patients as a bleeding-avoidance strategy after percutaneous coronary intervention. That was only one of the many takeaway messages from Saturday’s landmark session on antiplatelet therapy at CRT 2021 Virtual.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details